Covishield India: demystifying myths through an early multicenter study

Mohakuda, Sourya Sourabh; Nigam, Ankur; Rajesh, K S; Sashindran, VK; Sharma, Himanshu; Singh, Bhupender; Kaur, Ramanjot; Thawal, Mamta

doi:10.37765/ajmc.2021.88694

Cited by 2 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 34 ] In our study, ASHA workers showed the highest prevalence of AEFI among different occupations after the first dose, whereas most of the studies found no significant association between occupation and AEFI. [ 29 30 34 ] We found no significant association between marital status, residential area, religion, and AEFI.…”

Section: Discussionmentioning

confidence: 60%

“…[ 28 29 ] Mohakuda et al . [ 30 ] found that the odds of participants in the groups aged 29–39 years and 39–49 years developing minor reactions following exposure to the Covishield vaccine were 1.90 ( P =0.029) and 2.37 ( P =0.034), respectively, vs. those of participants in the group aged 19–29 years and Basavaraja et al . [ 31 ] found that the majority of the study population with AEFI belong to the age group of 18–45 years (82.53%).…”

Section: Discussionmentioning

confidence: 99%

“…Whereas a study conducted by Mohakuda et al . [ 30 ] found that the odds of men developing systemic AEFI to the Covishield vaccine were 2.08 times that of women. Some studies found no significant association of AEFI with gender,[ 29 36 ] but the prevalence was more among females.…”

Section: Discussionmentioning

confidence: 99%

“…Whereas there was a statistically insignificant association between the development of AEFI and comorbidity in studies by Mohakuda et al . [ 30 ] and Kaur et al . [ 33 ]…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India

Jha,

Kumar,

Goel

et al. 2024

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Objective: This study sought to assess the prevalence of adverse events following immunization (AEFI) and factors associated with AEFI of the ChAdOx1 nCoV-19 vaccine (Covishield) among healthcare workers (HCW) of a medicine-teaching institution of North India. Materials and Methods: A cross-sectional study was conducted in the months of June and July 2021 among HCW (N = 203) of 18 years and above, vaccinated with at least the first dose of Covishield. A semi-structured, prevalidated, and pretested questionnaire was used to collect information through an interview schedule. The questionnaire was divided into five sections: the sociodemographic profile, behavioral characteristics, past medical history, COVID-19 awareness, and past infection and COVID-19 vaccine related information. Chi-squared test was applied to check the association of different factors with AEFI. Results: In our study, 73.89% of participants suffered from at least one AEFI after the first dose of the vaccine, while 48.66% had at least one AEFI after the second dose. Females reported significantly high AEFI for both doses (P = 0.001, 0.000). We found a significant association between the occurrence of AEFI and occupation (first dose P = 0.015), substance abuse (first dose P = 0.002), diet (first dose P = 0.016), and allergy (first dose P = 0.027). Other significant findings were headaches among HCW ≥40 years of age (dose P = 0.034) and systemic AEFI in participants with comorbidity (first dose P = 0.020). Conclusion: More AEFI were reported after the first dose as compared to the second dose. AEFI were more among females after both the doses. Occupation, substance use, diet, and history of allergy were significantly associated with AEFI.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Whereas there was a statistically insignificant association between the development of AEFI and comorbidity in studies by Mohakuda et al . [ 30 ] and Kaur et al . [ 33 ]…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India

Jha,

Kumar,

Goel

et al. 2024

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

show abstract

“…Also seeing the high infectivity of the virus, social distancing and masks were being promoted to prevent its spread. [ 4 ]…”

Section: Introductionmentioning

confidence: 99%

Adverse effects after first and second dose of covishield and covaxin: A longitudinal study

Sachan¹,

Mittal²,

Jain³

et al. 2022

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

A BSTRACT Background: COVID-19 vaccines have been rolled out recently in several parts of the world. Although the protective efficacy is frequently discussed, little is known about the factors associated with COVID-19 vaccine adverse effects. The study was conducted with the aim to evaluate the occurrence of adverse events following immunization (AEFI) with two doses of covishield and covaxin and to assess factors associated with these adverse effects. Methods: A longitudinal study was conducted for a period of three months in the adults above 18 years of age attending rural health training center (RHTC) either to receive their first or second dose of covishield or covaxin. After vaccination, the participants were observed at the health facility for 30 min for any AEFI and also followed up telephonically on seventh day from vaccination. Data was collected on predesigned and pretested questionnaire and appropriate statistical tests were applied. Results: Out of 532 participants, 250 (47%) came for their first dose while 282 (53%) came for second dose. In both the groups maximum participation was seen by males and those belonging to age group 18–30 years. Majority of the participants reported local tenderness (39.3%) after first dose of covaxin and fever (30.5%) after first dose of covishield. Mainly significant association was observed after vaccination in participants with comorbidities. Conclusion: The short-term adverse events with both the vaccines were observed, but these were mild and short lived. In this context, our study becomes more relevant in disseminating short-term safety data post vaccination. This will help individuals in their decision to accept vaccination.

show abstract

Covishield India: demystifying myths through an early multicenter study

Cited by 2 publications

References 0 publications

Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India

Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India

Adverse effects after first and second dose of covishield and covaxin: A longitudinal study

Contact Info

Product

Resources

About